- ANGLE has announced that researchers have presented successful results from their work using the company's Parsortix system in colorectal cancer at the American Society of Clinical Oncology annual meeting in Chicago.

ANGLE said the study, undertaken by The University of Texas MD Anderson Cancer Center, represented the first ever analysis of meEGFR (arginine methylation of the epidermal growth factor receptor) status across a population of circulating tumour cells (CTCs) isolated from colorectal cancer patients being treated with EGFR inhibitors.

ANGLE said that meEGFR was already associated with a patient's likely response to EGFR inhibitors, a key drug class in the treatment of colorectal cancer.

The object of the study was therefore to assess whether the presence of meEGFR biomarker, when found in CTCs, is predictive of an adverse duration of progression-free survival (PFS) amongst this treatment group.

The results showed that in a prospective study of 47 metastatic colorectal cancer patients, researchers were able to use the Parsortix system to harvest circulating tumour cells (CTCs) and were able to analyse these cells for the presence or absence of meEGFR.

ANGLE founder and chief executive, Andrew Newland, said: "This colorectal cancer study adds to the body of evidence driving adoption of Parsortix in the fast growing liquid biopsy market.

"The ability to assess the patient's likely response to a particular drug as a companion diagnostic is a key element in the drive to provide precision medicine for patients saving money and improving treatment."

Story provided by